Current Edition


Gilead, following Merck, hits its own safety setback in HIV

The clinical hold comes at an inopportune time for Gilead. Last month, the company’s longtime rival Merck & Co. disclosed worrisome findings from a study …

Continue Reading →
active ingredient

A worrisome safety signal slows Merck’s HIV ambitions

Currently, the world’s best-selling HIV medications are made up of at least three “active ingredients.” But recent years have seen increasing interest in treatments that …

Continue Reading →